COVID infection in 4 steps: Thermodynamic considerations reveal how viral mucosal diffusion, target receptor affinity and furin cleavage act in concert to drive the nature and degree of infection in human COVID-19 disease.
Autorzy:
Popovic M; Institute of Chemistry, Technology and Metallurgy, University of Belgrade, Njegoševa 12, 11000 Belgrade, Serbia. Martin JH; Centre for Drug Repurposing and Medicines Research, University of Newcastle and Hunter Medical Research Institute, Newcastle 2305, Australia. HeadRJ; Drug Discovery and Development, Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, Australia.
Pokaż więcej
Źródło:
Heliyon [Heliyon] 2023 Jun; Vol. 9 (6), pp. e17174. Date of Electronic Publication: 2023 Jun 12.
Critical insights to COVID-19 disease and potential treatments using a systems analysis approach that integrates physiology, pharmacology, and clinical pharmacology.
Autorzy:
Martin JH; The University of Newcastle Hunter Medical Research Institute, New Lambton, New South Wales, Australia. HeadRJ; Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, Australia.
Systems analysis shows that thermodynamic physiological and pharmacological fundamentals drive COVID-19 and response to treatment.
Autorzy:
HeadRJ; Drug Discovery and Development, Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, Australia. Lumbers ER; School of Biomedical Sciences & Pharmacy, University of Newcastle, Newcastle, New South Wales, Australia.; Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia. Jarrott B; Florey Institute of Neuroscience & Mental Health, University of Melbourne, Parkville, Victoria, Australia. Tretter F; Bertalanffy Center for the Study of Systems Science, Vienna, Austria. Smith G; VP System Practice - International Society for System Sciences, Pontypool, UK. Pringle KG; School of Biomedical Sciences & Pharmacy, University of Newcastle, Newcastle, New South Wales, Australia.; Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia. Islam S; Drug Discovery and Development, Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, Australia. Martin JH; Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia.; Centre for Drug Repurposing and Medicines Research, Clinical Pharmacology, University of Newcastle, Newcastle, New South Wales, Australia.
Dietary butyrylated high-amylose starch reduces azoxymethane-induced colonic O(6)-methylguanine adducts in rats as measured by immunohistochemistry and high-pressure liquid chromatography.
Autorzy:
Le Leu RK; CSIRO Food & Nutrition, Adelaide, South Australia, Australia. Electronic address: . Scherer BL; CSIRO Food & Nutrition, Adelaide, South Australia, Australia. Mano MT; CSIRO Food & Nutrition, Adelaide, South Australia, Australia. Winter JM; Flinders Centre for Innovation in Cancer, Flinders University of South Australia, Bedford Park. Lannagan T; CSIRO Food & Nutrition, Adelaide, South Australia, Australia. HeadRJ; CSIRO Food & Nutrition, Adelaide, South Australia, Australia; University of South Australia, Adelaide, South Australia, Australia. Lockett T; CSIRO Food & Nutrition, Adelaide, South Australia, Australia. Clarke JM; CSIRO Food & Nutrition, Adelaide, South Australia, Australia.
Structure-activity relationship of butyrate analogues on apoptosis, proliferation and histone deacetylase activity in HCT-116 human colorectal cancer cells.
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies